RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"
Bryan Oronsky, Corey A. Carter, Scott Caroen, Curtis L. Scribner, Arnold L. Oronsky, Tony R. Reid
Abstract
The main mechanism of action of RRx-001, a pharmaceutically unprecedented sui generis Phase 3 small molecule that is derived from the aerospace industry, is clarified. RRx-001 has demonstrated anticancer activity through antiangiogenic, immune, epigenetic, antioxidant, apoptotic and nitric oxide (NO) pathways, resulting in its pleiomorphic description as an antiangiogenic/vascular normalizer.
Topics & Concepts
Small moleculeNitric oxideEpigeneticsCancer researchChemistryImmune systemCD47ApoptosisMedicinePharmacologyCell biologyImmunologyComputational biologyBiologyBiochemistryInternal medicineGenePhagocytosis and Immune RegulationErythrocyte Function and PathophysiologyImmune cells in cancer